Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$23.0K-97.90%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Richard Feldschuh
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 37
- Beta
- 0.26
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 1537.11
Financials
Revenue
$23.0K-97.9%Net Income
$-3.31MEBITDA
$-3.31MFree Cash Flow
$-2.51MEPS (diluted)
$-0.66Shares Outstanding (diluted)
4.99M+7.8%Operating Expenses
$0.00Cash & Debt
$5.79MReturn of Capital
$0.00Dividend per Share
$0.03Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $503.4K | $9.17M | $1.84 |
| 2024 | $2.13M | $536.3K | $0.11 |
| 2023 | $34.59M | $280.6K | $0.06 |
| 2022 | $-353.4K | $5.18M | $0.60 |
| 2021 | $-2.62M | $4.75M | $1.18 |
| 2020 | $-2.81M | $-1.71M | $-0.43 |
| 2019 | $-115.0K | $-495.7K | $-0.12 |
| 2018 | $-918.4K | $-885.8K | $-0.24 |
| 2017 | $-1.01M | $-1.24M | $-0.33 |
| 2016 | $1.84M | $1.46M | $0.33 |
| 2015 | $-7.44M | $-9.15M | $-2.38 |
| 2014 | $-4.05M | $-976.7K | $-0.26 |
| 2013 | $-11.56M | $-8.22M | $-2.01 |
| 2012 | $-2.10M | $1.19M | $0.29 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from DXR's reported EPS growth of 15.3% a year over 13 years.
- EPS in 5 years
- $3.75
- Implied price
- $29.99
- Return from $10.39
- 23.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $14.91 — today's price is already 30.3% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 4 | 6 | 8 | 10 | 12 |
|---|---|---|---|---|---|
| 5.3% | -1.7% | 6.6% | 12.9% | 18.0% | 22.4% |
| 10.3% | 2.9% | 11.6% | 18.3% | 23.6% | 28.2% |
| 15.3% | 7.6% | 16.7% | 23.6% | 29.3% | 34.1% |
| 20.3% | 12.3% | 21.8% | 29.0% | 34.9% | 39.9% |
| 25.3% | 16.9% | 26.8% | 34.3% | 40.5% | 45.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100-16.67%Social Signal Score
Mentions (3)
- Newsglobenewswire.com·1d ago·Neutral
Daxor to Showcase Blood Volume Analysis Platform at ASN Kidney Week 2026 Making its ASN debut, Daxor's BVA™ technology delivers precise volume measurement to optimize fluid management and improve complex kidney care. Key Highlights: Commercial Presence: Daxor exhibiting at Booth #390 during ASN Kidney Week 2026 in Denver, CO (October 21–25, 2026).
View source ↗ - Newsglobenewswire.com·13d ago·Negative
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026 FDA 510(k)-cleared next-generation diagnostic platform delivers 3x faster results with 50% less blood, setting a new standard for data-driven heart failure management. Key Highlights: Commercial Acceleration: Daxor to feature its FDA-cleared, next-generation Blood Volume Analyzer (BVA™) designed for rapid clinical adoption across hospital systems and outpatient clinics Clinical Evidence: Independent clinical inve
View source ↗ - Newsglobenewswire.com·35d ago·Positive
Daxor Corporation to Participate in the 10th Annual Lake Street Best Ideas Growth Conference Oak Ridge, TN, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces today that CEO and President Michael Feldschuh will participate in Lake Street's Tenth Annual Best Ideas Growth (BIG10) Conference in New York City, New York on Thursday, September 10th, 2026.
View source ↗
Earnings
Wed, Mar 10(in 5 months)
Typical surprise -483.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Aug 31$-0.66 vs $-0.06miss
- Fri, Aug 29$-0.07 vs $-0.11beat
Estimates and results for DXR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by DXR officers and directors.
- Bought
- $252k
- Sold
- —
31 trades
0 trades
- Feldschuh Michael Richardbought
- Michel Robert Jbought
- Jefferies Johnbought
- Jefferies Johnbought
- Michel Robert Jbought
- Feldschuh Jonathan Adambought
- Jefferies Johnbought
- Feldschuh Michael Richardbought
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in DXR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.